Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
242 hedge funds and large institutions have $4.44B invested in Mirati Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 97 increasing their positions, 71 reducing their positions, and 26 closing their positions.
54% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 26
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
5% more capital invested
Capital invested by funds: $4.2B → $4.44B (+$231M)
5% more funds holding
Funds holding: 230 → 242 (+12)
20% less call options, than puts
Call options by funds: $70.3M | Put options by funds: $87.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$105M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$99.9M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$75.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.7M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$33.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$165M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$63.9M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$48.7M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$41.3M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$38.5M |
MRTX Hedge Fund Activity: Q3 2022 in Review
242 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2022, worth a combined $4.44B — up 5.5% from $4.2B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new MRTX positions and 26 closed out — a net gain of 14 holders — while 97 added to existing stakes and 71 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $105M. The largest seller was Goldman Sachs, cutting an estimated $165M.
- 242 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2022, up from 230 in Q2 2022.
- Funds reported $4.44B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2022, up 5.5% quarter-over-quarter.
- 40 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2022 and 26 closed out, a net change of +14 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2022 was Adage Capital Partners, an estimated $105M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2022 was Goldman Sachs, an estimated $165M sold.
Based on aggregated 13F filings for Q3 2022.